Jorg R. Oddens

Duration of Androgen Suppression in the Treatment of Prostate Cancer

M. Bolla, Theodorus M. de Reijke, Geertjan van Tienhoven et al. · New England Journal of Medicine · 2009 · 966 citations · Full text

Medicine, Oncology, Urology +14

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

Samantha Cambier, Richard Sylvester, Laurence Collette et al. · European Urology · 2015 · 640 citations · Full text

Medicine, Oncology, Urology +12

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

Jorg R. Oddens, Maurizio Brausi, Richard Sylvester et al. · European Urology · 2012 · 512 citations

Medicine, Oncology, Urology +8

Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

Maurizio Brausi, Jorg R. Oddens, Richard Sylvester et al. · European Urology · 2013 · 379 citations · Full text

Medicine, Oncology, Urology +9

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

J. Alfred Witjes, Marek Babjuk, Joaquim Bellmunt et al. · European Urology · 2019 · 192 citations · Full text

Medicine, Oncology, Urology +16